Novo Nordisk to discontinue long-acting insulin Levemir next year amid incoming 65% price cut

In­sulin pow­er­house No­vo Nordisk will dis­con­tin­ue its long-act­ing in­sulin Lev­emir in the US next year amid an­tic­i­pat­ed sup­ply dis­rup­tions, a 65% price cut and as the com­pa­ny faces price ne­go­ti­a­tions with CMS for its oth­er in­sulins.

The Dan­ish drug­mak­er said sup­ply dis­rup­tions of Lev­emir Flex­Pen are ex­pect­ed in mid-Jan­u­ary 2024, but that the prod­uct “will be dis­con­tin­ued on April 1, 2024,” while the Lev­emir vial will be dis­con­tin­ued at the end of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.